Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade
Published version of a preprint
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The antiapoptotic protein BCL2 plays critical roles in regulating lymphocyte development and immune responses, and has also been implicated in tumorigenesis and tumor survival. However, it is unknown whether BCL2 is critical for antitumor immune responses. We evaluated whether venetoclax, a selective small-molecule inhibitor of BCL2, would influence the antitumor activity of immune checkpoint inhibitors (ICI). We demonstrate in mouse syngeneic tumor models that venetoclax can augment the antitumor efficacy of ICIs accompanied by the increase of PD-1+ T effector memory cells. Venetoclax did not impair human T-cell function in response to antigen stimuli in vitro and did not antagonize T-cell activation induced by anti–PD-1. Furthermore, we demonstrate that the antiapoptotic family member BCL-XL provides a survival advantage in effector T cells following inhibition of BCL2. Taken together, these data provide evidence that venetoclax should be further explored in combination with ICIs for cancer therapy. Significance: The antiapoptotic oncoprotein BCL2 plays critical roles in tumorigenesis, tumor survival, lymphocyte development, and immune system regulation. Here we demonstrate that venetoclax, the first FDA/European Medicines Agency–approved BCL2 inhibitor, unexpectedly can be combined preclinically with immune checkpoint inhibitors to enhance anticancer immunotherapy, warranting clinical evaluation of these combinations. This article is highlighted in the In This Issue feature, p. 1
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“agents with senolytic properties such as cardiac glycosides and the BCL2 inhibitor venetoclax improve cancer immunosurveillance in the context of immunogenic chemotherapy or immune checkpoint blockade.258,259”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [259]
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769
Veis, D. J., Sorenson, C. M., Shutter, J. R., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80065-m · Cited by 1,628
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Kamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Kumar, S., Kaufman, J. L., Gasparetto, C., Mikhael, J., Vij, R., Pegourie, B., Benboubker, L., Facon, T., Amiot, M., Moreau, P., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788786 · Cited by 523
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, C. S., Anderson, M. A., Pott, C., Agarwal, R., Handunnetti, S., Hicks, R. J., Burbury, K., Turner, G., Di Iulio, J., Bressel, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715519 · Cited by 433
PD-1 Blockade Expands Intratumoral Memory T Cells
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0210 · Cited by 405
Disappearance of the Lymphoid System in Bcl-2 Homozygous Mutant Chimeric Mice
Nakayama, K.-I., Nakayama, K., Negishi, I., Kuida, K., Shinkai, Y., Louie, M. C., Fields, L. E., Lucas, P. J., Stewart, V., Alt, F. W., et al. (1993) · Science · doi:10.1126/science.8372353 · Cited by 397
Nakayama, K., Nakayama, K., Negishi, I., Kuida, K., Sawa, H., & Loh, D. Y. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3700 · Cited by 395
Control of Apoptosis in the Immune System: Bcl-2, BH3-Only Proteins and More
Marsden, V. S., & Strasser, A. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141029 · Cited by 384
Cutting Edge: Increased Expression of Bcl-2 in Antigen-Specific Memory CD8+ T Cells
Grayson, J. M., Zajac, A. J., Altman, J. D., & Ahmed, R. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.3950 · Cited by 352
Anti-apoptotic BCL-2 family members in development
Opferman, J. T., & Kothari, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.170 · Cited by 347
Moreau, P., Chanan-Khan, A., Roberts, A. W., Agarwal, A. B., Facon, T., Kumar, S., Touzeau, C., Punnoose, E. A., Cordero, J., Munasinghe, W., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788323 · Cited by 271
Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells
Inozume, T., Hanada, K.-I., Wang, Q. J., Ahmadzadeh, M., Wunderlich, J. R., Rosenberg, S. A., & Yang, J. C. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fad2b0 · Cited by 233
Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis
Wojciechowski, S., Tripathi, P., Bourdeau, T., Acero, L., Grimes, H. L., Katz, J. D., Finkelman, F. D., & Hildeman, D. A. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070618 · Cited by 227
Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1151 · Cited by 148
Gene Expression in Antigen-Specific CD8+ T Cells During Viral Infection
Grayson, J. M., Murali-Krishna, K., Altman, J. D., & Ahmed, R. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.795 · Cited by 129
Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M., & Letai, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 128
Khaw, S. L., Mérino, D., Anderson, M. A., Glaser, S. P., Bouillet, P., Roberts, A. W., & Huang, D. C. S. (2014) · Leukemia · doi:10.1038/leu.2014.1 · Cited by 102
Haikala, H. M., Anttila, J. M., Marques, E., Raatikainen, T., Ilander, M., Hakanen, H., Ala-Hongisto, H., Savelius, M., Balboa, D., Von Eyss, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08541-2 · Cited by 75
Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia
Salem, A. H., Dunbar, M., & Agarwal, S. K. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000522 · Cited by 39
Lü, P., Fleischmann, R., Curtis, C., Ignatenko, S., Clarke, S. H., Desai, M. B., Wong, S. L., Grebe, K. M., Black, K., Zeng, J., et al. (2017) · Lupus · doi:10.1177/0961203317719334 · Cited by 36
Cited by
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma
Salam, R., Saliou, A., Bielle, F., Bertrand, M., Antoniewski, C., Carpentier, C., Alentorn, A., Capelle, L., Sanson, M., Huillard, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36124-9 · Cited by 132
Current status and future perspectives in targeted therapy of NPM1-mutated AML
Ranieri, R., Pianigiani, G., Sciabolacci, S., Perriello, V. M., Marra, A., Cardinali, V., Pierangeli, S., Milano, F., Gionfriddo, I., Brunetti, L., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01666-2 · Cited by 142
Metadata
- Authors
- Kohlhapp, F. J., Haribhai, D., Mathew, R., Duggan, R., Ellis, P. A., Wang, R., Lasater, E. A., Shi, Y., Dave, N., Riehm, J. J., Robinson, V. A., Do, A. D., Li, Y., Orr, C. J., Sampath, D., Raval, A., Merchant, M., Bhathena, A., Salem, A. H., Hamel, K. M., Leverson, J. D., Donawho, C., Pappano, W. N., & Uziel, T.
- Affiliations
- AbbVie (United States) (US)
- Genentech (US)
- 5Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
- Ain Shams University (EG)
- Corresponding author
- Pappano, William N.
- Uziel, Tamar
- ORCID
- Venue
- Cancer Discovery
- Published
- 2021-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 68-79
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3083749790
- Cited by
- 126
- References
- 26
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 31 · 2023: 25 · 2022: 23 · 2021: 14
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AbbVie
- Genentech
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- venetoclax, BCL-2 inhibition, immune checkpoint blockade, PD-1, effector T cells, Bcl-xL, antitumor immunity, combination cancer therapy, apoptosis, T cell memory
- MeSH terms
- Immune Checkpoint Inhibitors, Sulfonamides, T-Lymphocytes, Bridged Bicyclo Compounds, Heterocyclic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.